Zacks Research assumed coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) in a report released on Wednesday, Zacks reports. The brokerage set a “hold” rating on the stock. A number of other analysts have also issued reports on the stock. Guggenheim initiated coverage on shares of Retension Pharmaceuticals in a research report […]

Oppenheimer began coverage on shares of Retension Pharmaceuticals (NASDAQ:RTSN – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $50.00 price objective on the stock. Separately, Guggenheim began coverage on shares of Retension Pharmaceuticals in a research report on Monday. They issued a “buy” rating and a […]

HC Wainwright began coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) in a research note released on Thursday, MarketBeat reports. The brokerage issued a buy rating and a $55.00 price objective on the biopharmaceutical company’s stock. Several other research analysts have also recently weighed in on AGIO. Bank of America boosted their price […]